NCT01866319View on ClinicalTrials.gov

Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of Pembrolizumab (MK-3475) Compared to Ipilimumab in Participants With Advanced Melanoma (MK-3475-006/KEYNOTE-006)

PHASE3CompletedINTERVENTIONAL
Enrollment

834

Participants

Timeline

Start Date

August 28, 2013

Primary Completion Date

March 3, 2015

Study Completion Date

June 3, 2019

Conditions
Melanoma
Interventions
BIOLOGICAL

Pembrolizumab

10 mg/kg IV, administered Q2W or Q3W based upon randomization.

BIOLOGICAL

Ipilimumab

3 mg/kg IV Q3W.

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT01866319 - Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of Pembrolizumab (MK-3475) Compared to Ipilimumab in Participants With Advanced Melanoma (MK-3475-006/KEYNOTE-006) | Biotech Hunter | Biotech Hunter